Influenza Vaccine
Adverse events are more likely when influenza vaccine is used inconsistent with labeling
Published in Medical Letter on the CDC and FDA, February 12th, 2006
According to a study from the United States, "In June 2003, the U.S. Food and Drug Administration licensed a trivalent live, attenuated influenza vaccine (LAIV-T) for intranasal administration to healthy persons 5 to 49 years of age. Although prelicensure testing involved 20,228 vaccinees, clinical trials were not of sufficient size to detect rare adverse events reliably."
"[Our] objective was to identify adverse events reported following LAIV-T administration after licensure using all adverse events reported to the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Clostridium
Study identified epidemic, toxin gene-variant strain of Clostridium difficile - HIV/AIDS Vaccine
Report outlines behavioral and social issues in HIV vaccine trial in Thailand - Moneypox Risk Factors
Clinical characteristics of human monkeypox are the focus of review - Smallpox Vaccine
Report describes adverse events linked to smallpox vaccine in U.S. - Acute Bacterial Sinusitis
Biopharma company submits NDA for Orapem to treat respiratory tract and skin infections - Allergy & Immunology
PreHistin approval process to be conducted by OTC division of U.S. FDA - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
